Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study.
Article in Rheumatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
23 authors.
Leonardo PalazzoDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-2652-7447
Julius LindblomDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0003-1582-9471
Emelie Kihlgren OlssonDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.ORCID 0009-0007-6617-3659
Elena NikiphorouCentre for Rheumatic Diseases, King's College London, London, UK.ORCID 0000-0001-6847-3726
Chris WincupDivision of Medicine, Department of Rheumatology, Rayne Institute, University College London, London, UK.ORCID 0000-0002-8742-8311
Syahrul Sazliyana ShaharirFaculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.ORCID 0000-0002-9068-8114
Wanruchada KatchamartDivision of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.ORCID 0000-0002-8952-5967
Phonpen Akarawatcharangura GooDepartment of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand.ORCID 0009-0009-7611-9992
Lisa TrabocoSection of Rheumatology, Department of Medicine, St. Luke's Medical Center-Global City, Taguig, Philippines.ORCID 0000-0002-1952-7879
Yi-Ming ChenDivision of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung City, Taiwan, Republic of China.ORCID 0000-0001-7593-3065
James B LillekerDivision of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.ORCID 0000-0002-9230-4137
Dey DzifaRheumatology Unit, Department of Medicine and Therapeutics, University of Ghana Medical School, College of Health Sciences, Korle-Bu, Accra, Ghana.
Carlos Enrique Toro GutiérrezReference Center for Osteoporosis, Rheumatology and Dermatology, Pontificia Universidad Javeriana Cali, Cali, Colombia.ORCID 0000-0002-6084-7049
Carlo V Caballero-UribeDepartment of Medicine, Hospital Universidad del Norte, Barranquilla, Atlantico, Colombia.ORCID 0000-0002-9845-8620
Hector ChinoyDivision of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.ORCID 0000-0001-6492-1288
COVAD Study Group
Vikas Agarwal *Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.ORCID 0000-0002-4508-1233
Latika GuptaDivision of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.ORCID 0000-0003-2753-2990
Ioannis Parodis *Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. ioannis.parodis@ki.se.ORCID 0000-0002-4875-5395
Funding
King Gustaf V's 80-year Foundation FAI-2020-0741Nyckelfonden OLL-974804Professor Nanna Svartz Foundation 2021-00436Region Stockholm FoUI-955483Swedish Rheumatism Association R-969696Swedish Society of Medicine SLS-974449Ulla and Roland Gustafsson Foundation 2021-26
6 · The paper itself
Abstract
objectiveTo determine the occurrence of breakthrough COVID-19 infections (BIs) in patients with systemic lupus erythematosus (SLE) compared with patients with other rheumatic autoimmune diseases (rAIDs), patients with non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs).
methodsThe study was based on data from 7035 fully vaccinated respondents to the online COVAD questionnaire with SLE (N = 852), rAIDs (N = 3098), or nrAIDs (N = 414), and HCs (N = 2671). BI was defined as COVID-19 infection occurring in individuals vaccinated with ≥ 2 doses (or 1 dose of J&J) ≥ 14 days after vaccination and not after 6 months since the last vaccine dose. Data were analysed using linear and logistic regression models.
resultsA total of 91/852 (10.7%) SLE patients reported at least one BI. The frequency of BIs in SLE patients was comparable to that among HCs (277/2671; p = 0.847) and patients with nrAID (39/414; p = 0.552) but higher than that among patients with other rAIDs (235/3098; p = 0.005). No demographic factors or treatments were associated with BIs in SLE patients (p ≥ 0.05 for all). Joint pain was more frequent in SLE patients than in HCs (odds ratio [OR]: 3.38; 95% confidence interval [CI]: 1.89-6.04; p < 0.001) or nrAID patients (OR: 2.44; 95% CI: 1.04-5.75; p = 0.041). Patient with SLE did not report a higher frequency of hospitalisation or need for advanced treatment for COVID-19 infection compared with disease controls and HCs, respectively.
conclusionCOVID-19 vaccination conferred similar protection against COVID-19 infection in terms of frequency and severity in patients with SLE to that reported by healthy individuals.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study. · full record | Socratic